CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into as of December 20, 2019 (the “Effective Date”) by and between Sanofi, a French corporation (acting on its own behalf and on behalf of its Affiliates, “Sanofi”) and Sling Therapeutics, Inc., a Delaware corporation (“Licensee”). Sanofi and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • November 26th, 2024 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into as of December 20, 2019 (the “Effective Date”) by and between Sanofi, a French corporation (acting on its own behalf and on behalf of its Affiliates, “Sanofi”) and Sling Therapeutics, Inc., a Delaware corporation (“Licensee”). Sanofi and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • September 12th, 2024 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into as of December 20, 2019 (the “Effective Date”) by and between Sanofi, a French corporation (acting on its own behalf and on behalf of its Affiliates, “Sanofi”) and Sling Therapeutics, Inc., a Delaware corporation (“Licensee”). Sanofi and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”